AB

Annexon Biosciences

Biotechnology · South San Francisco, California, United States · Founded 2011

About

They target C1q to block all damaging components of the immune system’s classical complement pathway. Research output of 200-300 works, primarily in Medicine, Social Sciences, and Arts and Humanities.

Company details may include data from People Data Labs, licensed CC BY 4.0.